The guide to
Monoclonal Antibodies for Alzheimer's disease
What mab drugs are available today?
Mab drugs and brain bleeds
What are monoclonal antibodies?
narration
What are monoclonal antibodies?
Title 1
Monoclonal antibody drugs (or 'mab' in short) are used to treat many diseases, including cancer. It binds to a single antigen, and can be used alone or as delivery vehicles to carry other substances to the cells they’re searching for. Some mab drugs are considered immunotherapies, because they help the immune system recognize and destroy certain target cells.
Why are they called "mab drugs"?
What are they?
They are man-made immune cells that power drugs to treat cancer, osteoporosis, and other disorders.
What do they do?
Generic names of monoclonal antibodies often end in “mab”, such as trastuzumab, rituximab, and lecanemab.
They target and destroy foreign viruses, bacteria, plaques, or other unwanted pathogens in the body.
narration
How mab drugs fight Alzheimer’s
These Alzheimer’s anti-amyloid mab drugs prevent the buildup of amyloid plaques between brain cells.Both Leqembi and Kisunla attach to plaques. Leqembi also attaches to some forms of beta-amyloid before they become plaques.
Amyloid plaques block the communication among neural circuits and weaken brain function.
By seeking and binding to the plaques, monoclonal antibodies help clear them out of the brain.
narration
Alzheimer’s mab drugs on the market
Mab drugs on whole are still early in development, Experts say they show promise in slowing early-stage Alzheimer's. As of July 2024, only Leqembi (lecanemab) and Kisunla (donanemab) have been approved as a treatment for Alzheimer’s.
*CDR-SB: Clinical Dementia Rating–Sum of Boxes scale.
A higher score indicates more impairment.
narration
Learn more about Alzheimer’s mab drugs
Click the links below to read Being Patient's coverage on the latest -mab drugs.
Leqembi (FDA-approved July 6, 2023)
Kisunla (FDA-approved July 2, 2024)
narration
Mab drugs and brain bleeds
One side effect of Leqembi and Kisunla is brain bleeds, also called amyloid-related imaging abnormalities (ARIA). These tiny brain hemorrhages are typically so small they're asymptomatic and go undetected. However, in rare cases, they can be serious.
- Mab drugs target and remove beta-amyloid plaques in the brain, which can weaken brain blood vessels and cause bleeding.
- Individuals with the APOE4 gene have higher risk of bleeding due to higher accumulations of amyloid in their brains.
- While non-APOE4 carriers have a 5 percent risk of ARIA, carriers with one or two copies of the gene face a 15 and 33 percent risk respectively.
Read more
narration
The future of mab drugs for Alzheimer’s
The latest real world data on people taking Leqembi shows that it's safe and well-managed.
More data
As more people take mab drugs, scientists will gather long-term data to better understand their side effects and efficacy.
More access
So far, these drugs have been hard to get, in large part due to their format. Making these originally infusion-based Alzheimer’s mab drugs available in new formats, like pills, will help expand accessibility.
Read more about mab drug Research
narration
Want to learn more?
Visit
beingpatient.com
for the latest news and information on brain health and Alzheimer's disease
narration
UPDT - Monoclonal Antibodies
Deborah Kan
Created on October 22, 2025
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Discover Your AI Assistant
View
Vision Board
View
SWOT Challenge: Classify Key Factors
View
Explainer Video: Keys to Effective Communication
View
Explainer Video: AI for Companies
View
Corporate CV
View
Flow Presentation
Explore all templates
Transcript
The guide to
Monoclonal Antibodies for Alzheimer's disease
What mab drugs are available today?
Mab drugs and brain bleeds
What are monoclonal antibodies?
narration
What are monoclonal antibodies?
Title 1
Monoclonal antibody drugs (or 'mab' in short) are used to treat many diseases, including cancer. It binds to a single antigen, and can be used alone or as delivery vehicles to carry other substances to the cells they’re searching for. Some mab drugs are considered immunotherapies, because they help the immune system recognize and destroy certain target cells.
Why are they called "mab drugs"?
What are they?
They are man-made immune cells that power drugs to treat cancer, osteoporosis, and other disorders.
What do they do?
Generic names of monoclonal antibodies often end in “mab”, such as trastuzumab, rituximab, and lecanemab.
They target and destroy foreign viruses, bacteria, plaques, or other unwanted pathogens in the body.
narration
How mab drugs fight Alzheimer’s
These Alzheimer’s anti-amyloid mab drugs prevent the buildup of amyloid plaques between brain cells.Both Leqembi and Kisunla attach to plaques. Leqembi also attaches to some forms of beta-amyloid before they become plaques.
Amyloid plaques block the communication among neural circuits and weaken brain function.
By seeking and binding to the plaques, monoclonal antibodies help clear them out of the brain.
narration
Alzheimer’s mab drugs on the market
Mab drugs on whole are still early in development, Experts say they show promise in slowing early-stage Alzheimer's. As of July 2024, only Leqembi (lecanemab) and Kisunla (donanemab) have been approved as a treatment for Alzheimer’s.
*CDR-SB: Clinical Dementia Rating–Sum of Boxes scale. A higher score indicates more impairment.
narration
Learn more about Alzheimer’s mab drugs
Click the links below to read Being Patient's coverage on the latest -mab drugs.
Leqembi (FDA-approved July 6, 2023)
Kisunla (FDA-approved July 2, 2024)
narration
Mab drugs and brain bleeds
One side effect of Leqembi and Kisunla is brain bleeds, also called amyloid-related imaging abnormalities (ARIA). These tiny brain hemorrhages are typically so small they're asymptomatic and go undetected. However, in rare cases, they can be serious.
Read more
narration
The future of mab drugs for Alzheimer’s
The latest real world data on people taking Leqembi shows that it's safe and well-managed.
More data
As more people take mab drugs, scientists will gather long-term data to better understand their side effects and efficacy.
More access
So far, these drugs have been hard to get, in large part due to their format. Making these originally infusion-based Alzheimer’s mab drugs available in new formats, like pills, will help expand accessibility.
Read more about mab drug Research
narration
Want to learn more?
Visit
beingpatient.com
for the latest news and information on brain health and Alzheimer's disease
narration